Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
EAElisa A. RozemanAMAlexander M. MenziesACAlexander C. J. van AkkooiCMChandra Mani AdhikariCBCarolien Bierman
The Netherlands Cancer Institute · The University of Sydney · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
519
total citations
- FWCI
- 25.84
- Percentile
- 100%
- References
- 27
Citations per year
Authors
37- EAElisa A. Rozeman
The Netherlands Cancer Institute
- AMAlexander M. Menzies
The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia
- ACAlexander C. J. van Akkooi
The Netherlands Cancer Institute
- CMChandra Mani Adhikari
The University of Sydney, Melanoma Institute Australia
- CBCarolien Bierman
The Netherlands Cancer Institute
Topics & keywords
Topics
Keywords
- Ipilimumab
- Nivolumab
- Medicine
- Dosing
- Internal medicine
- Melanoma
- Clinical trial
- Oncology
UN Sustainable Development Goals
- No poverty
No related works found for this paper.